Mednet Logo
HomeRadiation Oncology
Radiation Oncology

Radiation Oncology

Expert insights on radiation treatment planning, techniques, toxicity management, and multimodal cancer care.

Recent Discussions

In a locoregionally advanced breast cancer with multiple positive surgical margins, how safe is it to wait for a re-excision vs treating upfront with comprehensive RT if surgery cannot be done the short term due to the COVID outbreak?

2 Answers

Mednet Member
Mednet Member
Radiation Oncology · Allegheny Health Network, Pittsburgh

Agreed, higher radiation dose will not replace negative margins. Obtaining negative margins is ideal. If the patient is a systemic therapy candidate, I would agree with @Dr. First Last and proceed with systemic therapy and then re-excision.

Should we consider radiation therapy for patients with N2 EGFRm NSCLC who will receive osimertinib, though RT was excluded on ADAURA?

2
4 Answers

Mednet Member
Mednet Member
Medical Oncology · University of Maryland

For an EGFR-mutant N2 disease, we favor adjuvant chemotherapy (OS benefit) and/or adjuvant TKI based on ADAURA trial (DFS survival). The only prospective data regarding the use of adjuvant radiotherapy comes from a phase III trial, Lung Adjuvant Radiotherapy Trial (Lung-ART), where patients were ran...

Have treatment recommendations changed for Stage I endometrial Cancer based upon PORTEC 4 results?

1 Answers

Mednet Member
Mednet Member
Radiation Oncology · University of Kentucky

PORTEC-4a will almost certainly change recommendations for adjuvant treatment in high-intermediate risk stage I patients with endometrial cancer, and in at least 2 different ways, in my opinion. By following the molecular profiling guidelines, nearly half of these patients will avoid adjuvant treatm...

How do you determine dose for prostate SBRT?

15
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · NYU Langone

The Stanford experience published by King et al was an important one describing a prospective experience of SBRT at dose levels of 35-36.25 Gy, and these dose levels were used based upon prior single institution retrospective reports from community practice settings where a good deal of experience ...

Is it necessary to use double contrast MRI for treatment planning of brain SRS?

3
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · GammaWest Cancer Services

"Necessary" is perhaps too restrictive a term, but speaking anecdotally, at Barrow Neurological Institute (BNI) we, for essentially the past 20 years, routinely obtain thin cut (1mm) SPGR double-dose gadolinium MRI to plan radiosurgery for patients with brain metastasis. In support of this, a recent...

What is your treatment algorithm for solitary hepatocellular carcinoma, 3-5 cm, non-operative candidate but Child-Turcotte Pugh A/B?

1
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Mayo Clinic, Rochester

This really boils down to two issues: CTP score and size of the lesion. For patients who are CTPA with a lesion <3 cm, RFA/MWA or SBRT are good options although there is some data from the University of Michigan (Wahl et al., JCO 2014) that lesions > 2 cm are better served with SBRT. For solitary le...

In a patient with rectal cancer, when would you consider brachytherapy monotherapy or brachytherapy boost after CRT?

3
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Mayo Clinic School of Medicine

For a patient with cT2N0 disease, the most appropriate use of brachytherapy would be sequential with pelvic radiotherapy, the bulk of data being with long-course CRT. Brachy can either be done prior to CRT or sequenced afterwards. We routinely use brachytherapy in appropriate candidates in our pract...

How would you approach a radiation-induced angiosarcoma of the breast after mastectomy with negative margins?

1
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · Varian Medical Systems/Allegheny health network

Based on this research we tend to offer RT for high grade or tumor more than 5 cm or RT induced; there is no good prospective data. Based on UF series, we offer accelerated hyperfractionation 1.5 BID to 45 to 50 Gy, treating only chest wall.

Does non-urothelial histology impact your approach to chemoradiotherapy for muscle-invasive bladder cancer?

1 Answers

Mednet Member
Mednet Member
Radiation Oncology · West Virginia University Hospitals

There is no randomized data available in this regard to guide us through non-urothelial histologies for MIBC. However, certain points that are worth considering in their management are: For small cell or neuroendocrine tumors, cisplatin/etoposide or ifosfamide/doxorubicin-based systemic therapy in ...

When do you consider re-irradiating patients with recurrent cervical cancer?

3
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · University of Kentucky

Because I have been seeing and treating a reasonable number of these cases for 35 years, I have some strong opinions on the matter. Although external beam re-irradiation in the setting of recurrent cervical cancer is fraught with great hazards and poor outcomes, interstitial re-irradiation has a hig...